SEER, US81578P1066

Seer stock: Company cuts 2026 revenue guidance

Published on 11/20/2026 at 00:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Seer stock faces a lower 2026 revenue outlook after third-quarter sales reached USD 4.0 million. The company also reported a narrower net loss.

Seer adjusts its outlook

  • Third-quarter revenue reached USD 4.0 million, while revenue declined 3% year over year.
  • Net loss narrowed to USD 13.7 million from USD 18.2 million in the year-earlier quarter.
  • Cash, cash equivalents and investments totaled approximately USD 198.1 million at September 30, 2026.
  • Management cited extended sales cycles and pressure on academic and government funding.
SEER, US81578P1066, Illustration mit AI erstellt.

Seer lowered its full-year 2026 revenue outlook on November 10 after reporting third-quarter results for the period ended September 30. The company now expects revenue of USD 13.5 million to USD 14.5 million, compared with its previous range of USD 16 million to USD 18 million.

In its November 10 release, Seer said continued pressure on academic and government funding had extended sales cycles. Several late-stage opportunities are now expected to close later than planned, putting the revised outlook below the earlier range.

Quarterly revenue remains under pressure

Third-quarter revenue was USD 4.0 million, compared with USD 3.1 million in the second quarter and USD 4.1 million in the year-earlier quarter. Product revenue contributed USD 2.8 million from Proteograph instruments and consumable kits, while service revenue was USD 1.1 million.

Gross profit was USD 1.9 million, producing a 47% gross margin. Operating expenses fell 23% to USD 16.5 million, including lower stock-based compensation, and the net loss narrowed to USD 13.7 million from USD 18.2 million a year earlier.

Cash position supports ongoing investment

Seer held approximately USD 198.1 million in cash, cash equivalents and investments at the end of September. Net cash used in operating activities reached approximately USD 34.5 million during the first nine months, while management said its current operating plan provides sufficient capital to reach cash-flow breakeven.

The company also said established customers continued to buy consumables and that new pharmaceutical customers adopted its platform. Seer announced on October 29 that it would remain an independent public company after a special committee review. On November 5, it reported that investigative staff at the U.S. International Trade Commission recommended the requested exclusion and cease-and-desist orders in its case involving Nanomics; a final commission decision remains pending.

Business model and market position

Seer is a life sciences company based in Redwood City, California, focused on deep proteomics for research and discovery. Its Proteograph Product Suite combines engineered nanoparticles, automated instruments, consumables and analytical software to expand access to protein information in biological samples.

The company serves research customers across population-scale studies, pharmaceutical development and AI-related applications. Its platform is intended for research use only and is not designed for diagnostic procedures.

Seer company facts

  • Company: Seer, Inc.
  • ISIN: US81578P1066
  • Ticker: SEER
  • Home exchange: Nasdaq
  • Headquarters: Redwood City, California
  • Core product: Proteograph Product Suite

The broader US equity market provides the relevant backdrop for Seer stock through the S&P 500 market overview.

More news and analyses are available in the Seer stock topic.

Disclaimer...
en | US81578P1066 | SEER | boerse | 70538178 | bgmi